Sales Battle Card: Octave Bioscience’s $51M Capital Boost
Octave Bioscience closes a $35.6M Series C + $15.5M term loan. Pipeline alert: pitch care management platform and biomarker analytics to CEO William Hagstrom. Lock your next touch and drive commission.
Published on
Do not index
Do not index
🚀 Battle Card: Octave Bioscience
Quick trigger:
👤 Decision Maker in the News
- William A. Hagstrom, CEO 📧 bill@octavebio.com
💡 Why It Matters
- This Octave Bioscience sales trigger provides $51.1M of capital to accelerate its biomarker-driven care management platform and expand into new neurodegenerative disease markets. → Source
🎯 Core Pain Point
- Demonstrating measurable patient outcomes to secure further funding
- Scaling platform deployment across neurologist practices
💰 What to Pitch
- Primary: Care Management Platform → Boost patient engagement and retention
- Expansion: Biomarker Analytics Integration → Enhance clinical decision support
🗺️ Quick Context
- HQ: Menlo Park, CA
- Employees: ≈ 75
- Rev: ≈ $10M
- Website: octavebio.com
🤼 Competitive Intel
Which other vendors you’ll probably face to win Octave Bioscience’s business.
- Qynapse — Digital biomarker analytics
- Unique edge: AI-driven MS progression modeling
- Evaluated by VP Product for algorithm accuracy
- Neurotrack — Cognitive biomarker platform
- Unique edge: Remote patient monitoring at scale
- Evaluated by Dir. Ops for engagement metrics
- Sophia Genetics — Data-driven clinical insights
- Unique edge: Genomic data integration
- Evaluated by CIO for IT compatibility
✅ Do-Now Checklist
Connect with William A. Hagstrom via email and mention this Octave Bioscience sales trigger
Use “Octave Bioscience sales trigger” in your email subject to boost open rates
Reference this Octave Bioscience sales trigger in your first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Get more “Octave Bioscience sales trigger” intel daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑≈ TBD❑
OFFER_BRIEF = ❑Our Care Management Platform that boosts patient engagement and retention❑
PROOF_METRIC = ❑30% increase in patient engagement❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = William
COMPANY = Octave Bioscience
DEPT = Ops
SIZE = 75
BOTTLENECK = scaling platform deployment across neurologist practices
EVENT = Closes $35.6M Series C
DETAIL = Closes $35.6M Series C
PAIN = Demonstrating measurable patient outcomes to secure further funding
SRC = https://vcnewsdaily.com/octave-bioscience/venture-capital-funding/vtxrzfzmhr
SIM_CO = Qynapse
WIN_METRIC = 30% faster platform rollout
NEXT_SIZE = ≈150
EMP_EST = ≈75
REV_EST = ≈$10M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 75-person Ops
William—noticed your Ops team is ≈ 75.
That’s when scaling platform deployment across neurologist practices slows growth.
We helped Qynapse fix this with Our Care Management Platform that boosts patient engagement and retention.
Result: 30% faster platform rollout.
Quick call?
PS—next bottleneck hits ≈ 150.
DM ≤45 words, TONE:
Saw your post about Closes $35.6M Series C — Demonstrating measurable patient outcomes to secure further funding.
Our Care Management Platform that boosts patient engagement and retention. 30% increase in patient engagement.
Quick chat?